Keytruda And Small Cell Lung Cancer

Food and drug administration has accepted merck s application seeking accelerated approval of keytruda pembrolizumab for the treatment of advanced small cell lung cancer sclc patients who failed at least two prior therapies.

Keytruda and small cell lung cancer.

The immunotherapy agent keytruda pembrolizumab had an overall response rate orr of 33 percent in a recent trial including patients with extensive stage small cell lung cancer sclc. Keytruda is a prescription medicine used to treat a kind of lung cancer called non small cell lung cancer nsclc. Keytruda may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread advanced nsclc and is a type called nonsquamous and your tumor does not have an abnormal egfr or alk gene. Findings of the phase 1b keynote 028 trial were published in the journal of clinical oncology.

Merck co s keytruda may be the star in non small cell lung cancer but a combo of it and chemo just failed to significantly outdo chemo alone at prolonging patients lives in small cell.